Breathe Well Live Well
|
Dynavax to Initiate Phase 1 Studies For TLR-9 Agonist For Asthma
Benzinga Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will advance AZD1419, a proprietary second-generation TLR-9 agonist for asthma, into Phase 1 clinical studies. Development expenses will be fully funded by AstraZeneca under … |
View full post on asthma – Google News
|
Dynavax and AstraZeneca Agree to Conduct Toxicology Studies for TLR-9 Agonist …
Healthcare Global (press release) These include demonstration that AZD1419 is capable of producing long lasting disease-modifying effects in a mouse model of atopic asthma. Under the terms of the amended 2006 research collaboration and license agreement, AstraZeneca will provide to … |
View full post on asthma – Google News
|
Dynavax and AstraZeneca Agree to Conduct Toxicology Studies for TLR-9 Agonist …
MarketWatch (press release) These include demonstration that AZD1419 is capable of producing long lasting disease-modifying effects in a mouse model of atopic asthma. Under the terms of the amended 2006 research collaboration and license agreement, AstraZeneca will provide to … |
View full post on asthma – Google News
|
Dynavax and AstraZeneca to Advance TLR-9 Agonist Into Clinic for Asthma
MarketWatch (press release) If AstraZeneca chooses to advance the program following completion of Phase 2a, Dynavax will receive a $20 million milestone payment, and AstraZeneca will retain its rights to develop the candidate therapy and to commercialize the resulting asthma … |
View full post on asthma – Google News